There cannot be many findings in the biological sciences that transformed medicine as much as CRISPR did. Initially discovered as the weird design in the genomes of bacteria, this adaptive immune system is the transformational piece of equipment in gene editing of humans and other living beings. CRISPR has the potential of treating genetic diseases, enhancing crops, and biotechnology faster than ever before, as is the case today. So how did a bacterial defense mechanism become one of the most potent of our biomedical instruments today? To realize this, we should trace the history of CRISPR- the discovery of the framework of CRISPR in bacteria to the advancement of the same into the game changer of human gene therapy.
The Accidental Findings: The CRISPR in Bacteria
At the end of the 1980s bacterial DNA researchers found odd repeated series alternating with unique spacers. These CRISPR which are short palindromic repeats regularly interspersed, appeared to play a role whose purpose was unknown. And what was a radical breakthrough only in the early 2000s was the realization that these DNA fragments were a kind of bacterial memory of earlier viral attacks.
Bacteria deploys their CRISPR arrays, together with Cas (CRISPR-associated) proteins that identify and kill attacking viral DNA. Bacteria that are infected by a virus are able to adapt the virus to enter a part of the virus DNA into the CRISPR locus. In future, when the same virus challenges again the bacterium transcribes these stored fragments into RNA and directs Cas proteins to snip and disable the viral genome. Such an adaptive immune process is very effective against the recurrence of infections by the bacteria, therefore offering them a very strong defense mechanism against the phages.
Nature Precision Scissors-The Role of Cas Proteins
Indeed, the CRISPR system is characterized with Cas proteins, which are molecular machines that can chop DNA at the desired location. Of all, Cas9 turned out to be the star. Initial Cas9 was discovered in the bacterium Streptococcus pyogenes and it uses guide RNA which is located in the bacterial CRISPR locus in order to identify similar DNA via complementary DNA sequence identification. Cas9 cleaves the target DNA as a double stranded break after binding.
Such an innate capacity to target specific sequences of DNA and chop them up made Cas9 a willing prospect in genetic engineering. Scientists discovered that they could just design synthetic guide RNAs that would reprogram Cas9 to go after almost any sequence in a genome.
CRISPR-Cas9 Eukaryotic Cells Adaptation
A major turning point of CRISPR development was the extension of the bacterial system of CRISPR-Cas9 to perform in eukaryotic cells–complexly organized organisms such as plants, animals, and humans.
By 2012, two groups have independently published breakthrough research to show that CRISPR-Cas could be used to edit genes in eukaryotic cells:
The secrets how the Cas9 could be programmed with custom guide RNAs to incise selected sites in any DNA were discovered by Jennifer Doudna and Emmanuelle Charpentier.
It has been shown that this system could be fine-tuned into effective mammalian cells and, therefore, it could be used in human and animal genomes by Feng Zhang and his laboratory at the Broad institute.
The adaptation was critical since it enabled scientists to generate specific mutations, correct and counteract disease-causing genes or even negate undesired genes as well as genetic components in the living cells.
Why the Shift to Gene Therapy of CRISPR is a Game-Changer
Zinc-finger nucleases and TALENs, typical traditional tools of gene-editing, were effective, however they were tedious and costly to design against new targets. CRISPR- Cas9 took the world by storm, because it was so simple, all that was required was a manipulation of the guide RNA sequence to point Cas9 at the new gene.
This flexibility has led to the CRISPR becoming a universal editing platform. CRISPR has never been previously used in gene therapy and has huge potential:
- Monogenic diseases: Diseases resulting due to inaccurate single gene such as sickle cell anemia, cystic fibrosis, or muscular dystrophy could be eliminated in theory by repairing the damaged gene in the cells of the sick.
- Cancer cure: Knocking out some genes that assist cancer cells to avoid immune system detection or redesigning the immune cells to identify more tumor cells is new territory CRISPR can break in cancer treatment.
- Infectious diseases: Scientists are developing to manipulate the viral genes themselves, e.g. latent HIV, within infected cells.
- Preventive treatments: Germline editing may help to prevent the transmission of some hereditary illnesses to the future generations and this would help avoid some hereditary illnesses, although this would bring in a much deeper ethical question.
Special Turning points in the Development of CRISPR Technology
To have a better understanding of the transformation of CRISPR defense mechanism in bacteria to therapeutic gene editing, it is beneficial to consider its most significant milestones:
Initial remarks (1987 -2000)
Japanese scientists have already documented the repeated sequences of DNA in E. coli, although its reason was unclear.
Similar trends were observed by other species of bacteria within the 1990s.
Appreciation of CRISPR as an Immune System (2002 2007)
The CRISPR acronym was coined in the year 2002.
In 2005 scientists correlated the CRISPR spacer sequences to bacteriophage DNA and implied an immune memory.
In 2007, a group showed experimentally that CRISPR could defend bacteria against viruses, and predicted that it serves as an adaptive immune system.
The Discovery and Repurposing of Cas9 (2011The discovery and Repurposing of Cas9 (20112013)
The research clarified the role of Cas9 in the targeting and cleaving of bacteria DNA.
2012: Doudna and Charpentier wrote a breakthrough paper, demonstrating that the Cas9 could be directed with synthetic RNAs to cut DNA in a programmed fashion.
In 2013, Feng Zhang group demonstrated that CRISPR-Cas9 could apply to eukaryotes and was successfully used in human cells.
Development – (2016 Present) Start of Clinical Applications (2016 Present)
CRISPR In 2016, the first human trials of CRISPR were initiated in China, focused on lung cancer.
Clinical trials: The experimental use of CRISPR to treat sickle cell disease and beta-thalassemia was carried out on patients in 2020, and its preliminary performance was impressive.
Nobel Prize in Chemistry 2020 Doudna and Charpentier won this award in 2020, having created CRISPR-Cas9 as a genome-editing technology.
The Wider Relevance of Modern Medicine
The fact that it will be possible to edit DNA in a precise and high throughput manner has far more implications than fixing rare genetic disorders:
- Agriculture: CRISPR will enable generating crops resistant to drought, pests, or disease, therefore, less pesticide is required and food security can be improved.
- Drug Discovery: Biologists can make cell and animal models with distinct mutations, making it even faster to find new cures to many kinds of diseases.
- Synthetic biology: This emerges as a whole biological pathways can be redesigned and this is the way to achieve new biomaterials and biofuels and engineered microbes.
Nevertheless, with CRISPR going from the lab to a clinic, there are ethical, legal, and social issues along with it. There are worries about the unintended off target mutations, the creation of designer kids via germline editing, and accessibility of these revolutionary remedies to all people.
Breaking Difficulties Specificity And Delivery
Although CRISPR revolutionized the field of molecular biology, there are still major setbacks in the way of the technology realizing its full therapeutic potential:
- Off-target effects: Cas9 has the undesirable characteristic of cutting at unintended locations and thus might have deleterious mutations. To make higher-fidelity, researchers have created higher-fidelity variants of Cas9 and base editors to raise accuracy levels.
- Effective spread: One of the limitations of CRISPR is distribution of its components to the appropriate cells of the body. In order to overcome this, viral vectors, lipid nanoparticles, and novel delivery styles are in pipe.
In spite of these issues it has been moving very fast and crispr based treatment is progressing into clinical trials.
Future Prospects: Past Cas9
The finding other Co-related proteins like Cas12 and Cas13 has increased the number of tools:
- Cas12: It also has the ability to cleave DNA, but, again with some unique DNA editing traits that could enhance reduced off-target engagement.
- Cas13: does not use DNA as a target and in fact can be used to temporarily inactivate gene expression or as a way to prevent RNA viruses such as SARS-CoV-2.
In the intervening time, a new technology, prime editing, a variant of CRISPR that also incorporates reverse transcriptase, uses the same search-and-replace scheme but without chopping both strands of DNA, and thus may lead to fewer errors and greater safety.
Conclusion: An Outstanding Transformation of Defence to cure
The fact that the CRISPR system moved, in a relatively short period of time, out of the shadow of bacterial immune system and into the spotlight of modern gene therapy is one of the most stunning stories in science. Its discovery would revolutionize our know-how of microbial defense and offer us a beautiful and programmable method of manipulating genomes in a way that was never possible beforehand.
Outlining the history of CRISPR technology in its discovery and current uses, we can appreciate the fact that the fundamental scientific research in bacterial immunity formed the background of technological advances in the fields of medicine, agriculture, and many more. With each high-profiled scientific development and as the science world attempts to navigate both the ethical and legal dilemmas of gene editing, more than a previously secret weapon used by bacteria, this simple development is transforming what can be done to improve human health and the planet.
